Skip to nav Skip to content

Clinical Trial Search

304 Clinical Trials Found

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
PI: Locke, Frederick

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 22464

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)
Disease Site: Thyroid
PI: Agosto Salgado, Sarimar

Clinical Trial 23101

Disease Site: Other Hematopoietic
PI: Fernandez, Hugo

Clinical Trial 20274

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Disease Site: Lip, Oral Cavity and Pharynx
PI: Kirtane, Kedar

Clinical Trial 20487

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Disease Site: Brain and Nervous System, Breast, Leptomeningeal (LMD)
PI: Ahmed, Kamran

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21559

Disease Site: Prostate
PI: Zhang, Jingsong

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 21416

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Disease Site: Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21158

Disease Site: Lung
PI: Gray, Jhanelle